Digital ulcers have a significant clinical burden in patients with systemic sclerosis. In a study presented today, Feb. 19, at the 4th Systemic Sclerosis World Congress (Feb. 18-20) in Lisbon, Portugal, an international team of researchers revealed that a medical history of digital ulcers in the past 24 weeks should trigger…
News
EUSTAR Study on Early SSc and Organ Manifestations Presented at Systemic Sclerosis World Congress
A EUSTAR study on organ manifestations in the early course of systemic sclerosis (SSc) was presented today, Feb. 19, by Dr. V.K. Jaeger at the 4th Systemic Sclerosis World Congress, now underway in Lisbon, Portugal. The presentation was titled “Incidences and Predictors of Organ Manifestations in the Early…
https://sclerodermanews.com/wp-content/uploads/videos/Sequence%2001_1.mp4 Scleroderma News Today’s exclusive interview with Professor Christopher Denton, lead investigator of two Phase 3 clinical trials assessing Bayer’s class of sGC stimulators, Adempas, in PAH and PAH-CTD patients. The 4th Systemic Sclerosis World Congress opened on Friday…
A team of researchers from University College London and Actelion Pharmaceuticals showed that macitentan (Opsumit) can prevent pulmonary arterial hypertension (PAH) in a mouse model of systemic sclerosis (SSc) by preventing heart tissue remodeling and functional changes. The results were presented this week by E. Derrett-Smith at the 4th…
Men with systemic sclerosis (SSc) who develop pulmonary arterial hypertension (PAH) tend to have poorer survival rates in the first five years after diagnosis, a University of Toronto study reported. Men were also found to develop PAH at an earlier stage in comparison to women, and to suffer a more…
Cytori Therapeutics recently announced its participation in the 4th World Systemic Sclerosis World Congress taking place Feb. 18-20, 2016, in Lisbon, Portugal. In a presentation titled “Treating Scleroderma of the Face and Hands with Fat and Stromal Vascular Fraction,” Professor Guy Magalon from the Assistance Publique des Hôpitaux…
Patients with connective tissue disease or systemic sclerosis associated with pulmonary arterial hypertension (PAH) who are positive for anti-U1 RNP antibodies have more a favorable disease prognosis than patients without these antibodies, a study published in the journal Arthritis & Rheumatology showed. Anti-U1 RNP antibodies are autoantibodies directed at nuclear proteins. They are…
The 4th Systemic Sclerosis World Congress, organized by the World Scleroderma Foundation (WSF), will run Feb. 18–20 at the Lisbon Congress Center in Lisbon, Portugal, and Scleroderma News Today will be there to cover and report on the proceedings The first three Systemic Sclerosis World Congresses — held…
Connective Tissue Diseases Like Scleroderma, Race and Age Increase Risk for Cardiovascular Disease
New research from the University of Chicago Medical Center indicates that African-Americans with connective tissue diseases, including scleroderma, are twice as likely as Caucasians with the same medical conditions to have specific risk factors for a heart attack, stroke, or cardiovascular-related death. The study, “The Prevalence of…
Fibrocell Science, Inc., recently highlighted the latest advancements in its pipeline of products focused on autologous cell and gene therapy treatments for several conditions, including scleroderma. The company’s autologous fibroblast technology uses a patented manufacturing process that involves collecting small skin biopsies from patients, separating the tissue into its component cells, and then…
Recent Posts
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc
- Coping with loss is part of living with scleroderma
- CAR T-cell therapy eases SSc symptoms, early trial data show
- Milk-derived particles may offer treatment path for SSc fibrosis